Olomorasib+Chemoimmunotherapy in KRAS G12C-Mutant NSCLC: Results from LOXO-RAS-20001 and SUNRAY-01

Pneumologie 2026

View at publisher
Authors: M.V. Negrao, James Uyeki, I Cicin, Y Chen, Byoung Yong Shim, Masafumi Yamaguchi, Timothy Francis Burns, Garrett Sherwood, Joseph Nicholas Bodor, J. Sakakibara-Konishi, Konstantin H. Dragnev, Natraj Reddy Ammakkanavar
+9 more VT G Lin, S Y Kim, Y Zhou, Nicolas Fasnacht, Aaron Alan Fink, Carla Visseren‐Grul, M Willard, S Peters, J Kollmeier
DOI: 10.1055/s-0046-1816483
Cited by: 0

Abstract

Background: Olomorasib demonstrated promising antitumor activity and a manageable safety profile in first-line (1L) KRAS G12C-mutant advanced NSCLC. Here, we report results of 1L patient (pts) from LOXO-RAS-20001 and the safety lead-in for SUNRAY-01. Methods: Pts with advanced KRAS G12C-mutant NSCLC, PD-L1 0-100% (ECOG PS 0-1) were assigned to olomorasib (50/100 mg, orally BID) with pembrolizumab+chemotherapy (chemo-IO). One prior cycle of standard of care (SOC) was allowed. Results: As of 15 January 2025, 78 pts received olomorasib+chemo-IO, including 24 pts (31%) who received 1 cycle of SOC prior to enrollment; 35% were PD-L1

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers Lung Cancer Diagnosis and Treatment

Publication details

Journal / source
Pneumologie
Volume
80
Publication date
1 March 2026
Language
EN